Upcoming event
ASCO Annual Meeting 2023
Back

Tags

Article of the Month, ASCO GU22, ASCO21, AUA21, Cabozantinib, Carcinoma, Chronic kidney disease, Cryosurgery, EAU, EAU21, EAU22, EMUC21, EMUC22, ERUS22, ESMO21, Frail patient​, Glomerular filtration rate, Guidelines, IMDC risk model, Kidney cancer, Laparoscopy, Lymph node metastases, Lymph nodes, Metastasectomy, Mortality, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, Overall survival, Partial nephrectomy, Prognostication, Radical nephrectomy, Radical surgery, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, Robotic, Robotic prostatectomy, Robotic surgery, Survival outcome, Suture, Targeted therapies, Treatment response, Urological surgery, UROwebinar, Webinar
Show all

Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time

BJU International, March 2023

View

Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma

European Urology Oncology, October 2023

View

Oncological and peri-operative outcomes of percutaneous cryoablation of renal cell carcinoma for patients with hereditary RCC diseases – An analysis of European multi-centre prospective EuRECA registry

View

Is adjuvant immunotherapy worth for all patients with clear-cell renal cell carcinoma at high risk of recurrence?

View

Deciphering the relationship between pathogenic variants and clinical phenotype in VHL patients: results from a prospective observational study

View
webcasts

Development of an individual postoperative prediction model for kidney cancer recurrence using machine learning (UroCCR study 120)

View

Quality of life outcomes after robotic-assisted versus open partial nephrectomy: Results from the randomized ROBOCOP II trial

View

89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma – results from phase 3 ZIRCON study

View

Local treatment of recurrent renal cell carcinoma may have a significant survival effect across all risk-of-recurrence groups

European Urology Open Science, January 2023

View

Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC)

View

Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK)

View

STARLITE 2: Phase 2 study of nivolumab plus 177lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)

View
Next